Kaitlin A. Pruskowski

Dr. Kaitlin A. Pruskowski


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Burns
Verified
Journal Article
Closed access
KPKaitlin A. Pruskowski
Kaitlin A. Pruskowski
JGJennifer M. Gurney
Jennifer M. Gurney
LCLeopoldo C. Cancio
Leopoldo C. Cancio

1 February 2021 in Surgical Infections
Verified
Journal Article
Closed access
KPKaitlin A. Pruskowski
Kaitlin A. Pruskowski
Background: Infection is common after burn injury and accounts for the most frequent complications of burn injury. This review describes the effects of burn injury on pharmacokinetics, focusing on the impact of these changes on antimicrobial therapy. Methods: The published literature on pharmacokinetics and pharmacodynamics in burn injury of antibiotic use was reviewed. Results: Physiologic and metabolic changes of burn injury can alter pharmacokinetic parameters, leading to larger volumes of distribution, faster hepatic metabolism, and increased renal clearance. Changes in pharmacokinetics may lead to subtherapeutic doses of commonly used antibiotic and antifungal agents. Conclusions: Although not all antimicrobial agents are well studied in the burn population, dose recommendations exist for some agents. Additional research is needed to cover the systemic antimicrobial agents used in the care of burn patients so that appropriate dosing adjustments can be made to optimize outcomes.

1 October 2021 in European Burn Journal
Verified
Journal Article
Open access
PDF file
KPKaitlin A. Pruskowski
Kaitlin A. Pruskowski
TMThomas Mitchell
Thomas Mitchell
JKJohn L Kiley
John L Kiley
TWTrevor Wellington
Trevor Wellington
GBGarrett Britton
Garrett Britton
Leopoldo C. CancioLeopoldo C. Cancio
Leopoldo C. Cancio
Invasive fungal wound infection (FWI) after burn injury, while uncommon, is associated with significant morbidity and mortality. There are numerous risk factors for FWI, including large burn size and incomplete excision of burn wounds. FWI can be challenging to diagnose. Close attention to changes in the physical examination and, in particular, to the appearance of burn wounds leads the burn team to be suspicious of FWI. Once FWI is suspected, histopathological evaluation of an incisional biopsy provides definitive diagnosis, while tissue culture enables identification of the causative organism to the species level and facilitates targeted antifungal therapy. Management of FWI focuses largely on aggressive surgical intervention, in addition to adjunctive systemic and topical antifungals and nonpharmacologic therapies. Treatment of FWI involves a multifaceted approach, which requires expertise from the entire multidisciplinary burn team.

1 February 2019 in Burns
Verified
Journal Article
Closed access
JRJulie A. Rizzo
Julie A. Rizzo
KPKaitlin A. Pruskowski
Kaitlin A. Pruskowski
TLTuan Le
Tuan Le
JGJennifer Gurney
Jennifer Gurney
MRMatthew P. Rowan
Matthew P. Rowan
LCLeopoldo C. Cancio
Leopoldo C. Cancio

1 March 2018 in Burns
Verified
Journal Article
Closed access
JRJulie A. Rizzo
Julie A. Rizzo
AMAngela K. Martini
Angela K. Martini
KPKaitlin A. Pruskowski
Kaitlin A. Pruskowski
MRMatthew P. Rowan
Matthew P. Rowan
KNKrista L. Niece
Krista L. Niece
KAKevin S. Akers
Kevin S. Akers

4 May 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
DSDaniel Selig
Daniel Selig
KAKevin S. Akers
Kevin S. Akers
Kevin Kien Hoa ChungKevin Kien Hoa Chung
Kevin Kien Hoa Chung
AKAdrian T. Kress
Adrian T. Kress
JLJeffrey R. Livezey
Jeffrey R. Livezey
JDJesse P. DeLuca
Jesse P. DeLuca
Critical illness caused by burn and sepsis is associated with pathophysiologic changes that may result in the alteration of pharmacokinetics (PK) of antibiotics. However, it is unclear if one mechanism of critical illness alters PK more significantly than another. We developed a population PK model for piperacillin and tazobactam (pip-tazo) using data from 19 critically ill patients (14 non-burn trauma and 5 burn) treated in the Military Health System. A two-compartment model best described pip-tazo data. There were no significant differences found in the volume of distribution or clearance of pip-tazo in burn and non-burn patients. Although exploratory in nature, our data suggest that after accounting for creatinine clearance (CrCl), doses would not need to be increased for burn patients compared to trauma patients on consideration of PK alone. However, there is a high reported incidence of augmented renal clearance (ARC) in burn patients and pharmacodynamic (PD) considerations may lead clinicians to choose higher doses. For critically ill patients with normal kidney function, continuous infusions of 13.5–18 g pip-tazo per day are preferable. If ARC is suspected or the most stringent PD targets are desired, then continuous infusions of 31.5 g pip-tazo or higher may be required. This approach may be reasonable provided that therapeutic drug monitoring is enacted to ensure pip-tazo levels are not supra-therapeutic.